Dehydration

IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years

Retrieved on: 
星期五, 一月 12, 2024

WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora. The launch of Fecal Dx antigen testing with Cystoisospora is planned for March in North America and globally in Q3 2024, available at IDEXX Reference Laboratories.

Key Points: 
  • IDEXX's Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora.
  • The launch of Fecal Dx antigen testing with Cystoisospora is planned for March in North America and globally in Q3 2024, available at IDEXX Reference Laboratories.
  • "We are thrilled to announce the second expansion of the Fecal Dx antigen testing platform in less than two years, reinforcing our commitment to continuous innovation," said Jay Mazelsky, President and Chief Executive Officer of IDEXX.
  • Cystoisospora will automatically be included in Fecal Dx antigen testing panels and profiles at the time of launch with no additional charge to customers.

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

Retrieved on: 
星期一, 一月 8, 2024

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update on the company’s progress in 2023 and initial expectations for 2024.

Key Points: 
  • “2023 was a landmark year for Ardelyx, marking our first full year as a commercial entity and the approval and launch of our second first-in-class product.
  • XPHOZAH® joins IBSRELA in our portfolio of important treatment options for patients with unmet needs,” said Mike Raab, president and chief executive officer.
  • We are poised to continue with a growth trend in 2024.
  • Ardelyx currently expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
星期四, 一月 4, 2024

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

Retrieved on: 
星期三, 一月 3, 2024

The event is being held at Convene, located at 100 Stockton Street, San Francisco, Calif. and will be webcast live.

Key Points: 
  • The event is being held at Convene, located at 100 Stockton Street, San Francisco, Calif. and will be webcast live.
  • A link to the webcast can be accessed on the Investors section of the company's website at www.ardelyx.com .
  • The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.
  • IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024

Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pemetrexed Sandoz, pemetrexed, Date of authorisation: 18/09/2015, Revision: 8, Status: Authorised

I collect marsupial poo. A crack team of volunteers across Australia helps me out

Retrieved on: 
星期六, 十二月 30, 2023

So his enthusiasm for the idea caught me by surprise.

Key Points: 
  • So his enthusiasm for the idea caught me by surprise.
  • He helpfully suggested several interesting topics: sea turtles, dugongs and coral reefs.
  • Much to my hubby’s dismay, I chose to immerse myself in the subject of marsupial poo – and in retaliation he started calling me Dr Poo.

The Marsupial Microbiome Poop Troop

  • We did this to establish a baseline of what the normal wild gut microbiome looks like in different animals in different areas at different times of the year.
  • This lets us recognise if there is an imbalance in captive animals that can be addressed and prevented by changing diet or introducing supplements.
  • To aid my communication with these wonderful volunteers, I started a Facebook group page which became known as the Marsupial Microbiome Poop Troop.
  • There is Kate, who obtains the freshest wombat poo by stalking wild wombats in her local reserve until they produce the goods.
  • The supervisor of the university’s stores, who receives the poo parcels, is not always a fan of Julie’s efforts.

Saving orphaned joeys

  • We have a particular focus on young orphaned joeys.
  • Whether their mothers were hit by cars, attacked by dogs, or died of other causes, the joeys arrive at wildlife shelters stressed, often injured, and generally cold and hungry.
  • The gut microbiome of these “pinky” joeys is equivalent in development to that of premature human babies.


Angela Russell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Nonprofit BlinkNow Provides Aid for Jajarkot Earthquake Crisis in Nepal

Retrieved on: 
星期三, 十二月 20, 2023

BlinkNow is celebrating this year of deepening roots and meaningful growth, which led to the opportunity to serve people in the surrounding region when disaster struck.

Key Points: 
  • BlinkNow is celebrating this year of deepening roots and meaningful growth, which led to the opportunity to serve people in the surrounding region when disaster struck.
  • Kopila Valley staff and volunteers traveled for hours through mountainous regions to deliver supplies to the hardest-hit areas of the earthquake.
  • This included clearing roads, geo-tagging distribution routes for others, and driving farther than other aid agencies may be able to reach.
  • The BlinkNow Foundation was founded in 2007 and provides an education and a loving, caring home for children without homes, impoverished and at-risk children.

Global Coconut Water Market Insights and Forecast to 2027 - Huge Gap between the Two Ends of the Coconut Water Supply Chain - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 19, 2023

The "Global Coconut Water Market (By Type, Form, Packaging, Distribution Channel, & Region): Insights and Forecast (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coconut Water Market (By Type, Form, Packaging, Distribution Channel, & Region): Insights and Forecast (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, increasing inclination of consumers towards health and wellness has boosted the consumption of coconut water and encouraged the market overall growth.
  • So it is that the stark gap between the two ends of the coconut water supply chain is only growing further apart.
  • Consequently, the huge gap between the two ends of the coconut water supply chain limits the coconut water market growth.